PMA device
InterStim Therapy System, Verify Evaluation System
Medtronic Neuromodulation · Implanted Electrical Device Intended For Treatment Of Fecal Incontinence (QON, Class III) · First FDA decision Apr 10, 2012, newest Nov 26, 2025Fecal incontinence and constipation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
20
PMA pathway
Device trials
28
Naming "InterStim Therapy"
MAUDE reports
0
Brand "InterStim Therapy", since 2015
PubMed studies
37
Mentioning "InterStim Therapy"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing InterStim Therapy System, Verify Evaluation System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 20 decisions filed under this name.
- InterStim Therapy System, Verify Evaluation SystemPMA supplement
P080025-S334 · Decided Nov 26, 2025 · 41 days after receipt · Normal 180 Day Track No User Fee
Device type: Implanted electrical device intended for treatment of fecal incontinence (QON) · GI, Urology & Nephrology
5 more FDA decisions with a free account
Older decisions: P080025-S248, P080025-S240, P080025-S237, P080025-S235, P080025-S197, P080025-S187, P080025-S163, P080025-S151, P080025-S142, P080025-S113, P080025-S068, P080025-S049, P080025-S046, P080025-S016
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Sacral Nerve Stimulation for the Treatment of Urinary and Fecal IncontinenceLocal determinationIn effectL39543Palmetto GBAUpdated Sep 12, 2023
- Electrical Stimulation (ES) and Electromagnetic Therapy for the Treatment of WoundsNational determinationOn the books270.1Updated Nov 4, 2026
- Pelvic Floor Electrical Stimulation for Urinary IncontinenceNational analysisReview closedCAG-00021NUpdated Sep 15, 2026
- Electrical Aversion Therapy for Treatment of AlcoholismNational determinationOn the books130.4Updated Jun 10, 2020
- Biofeedback Therapy for the Treatment of Urinary IncontinenceNational determinationOn the books30.1.1Updated Sep 24, 2015
- Home Health-Surface Electrical Stimulation in the Treatment of DysphagiaLocal determinationIn effectL34565Palmetto GBAUpdated Nov 21, 2023
- Surface Electrical Stimulation in the Treatment of DysphagiaLocal determinationIn effectL34578Palmetto GBAUpdated Aug 7, 2023
Clinical trials
Device studies on ClinicalTrials.gov that name "InterStim Therapy", any status and sponsor, newest update first.
Corewell Health EastAcademic, hospital or other
NCT06150599 · 25 participants (planned) · Start Jan 27, 2026 · Primary completion Apr 1, 2028
Device: Sacral neuromodulation · For: Chronic Pelvic Pain Syndrome
Sites: Royal Oak, Michigan
27 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "InterStim Therapy", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QON
10 reports: 3 malfunction, 7 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Enhanced Verify Evaluation Handset (CFN HH90130FA)Open, Classified
Z-1704-2025 · Started Apr 3, 2025 · Posted by FDA Apr 30, 2025
Reason given: Evaluation handsets may not be able to communicate with the neurostimulator due to handsets having a faster processing speed than prior handsets. An inability to connect may cause the therapy to stop being delivered and a system error will be displayed. Patient may experience return of underlying disease symptoms...
Cause as FDA categorized it: Device Design · Device type: Stimulator, Electrical, Implantable, For Incontinence (EZW)
4 more recall records with a free account
Published research
The most relevant PubMed records for "InterStim Therapy"[tiab]. The summary above synthesizes these.
- Outcomes associated with Interstim therapy for medically refractory fecal incontinence.
McNevin MS, Moore M, Bax T · Am J Surg · 2014Evaluation Study
- Sacral nerve stimulation: Interstim therapy.
Peeren F, Hoebeke P, Everaert K · Expert Rev Med Devices · 2005Review
- InterStim Therapy: A Contemporary Approach to Overactive Bladder.
Kohli N, Patterson D · Rev Obstet Gynecol · 2009
- Sacral Neuromodulation in Patients With a Cardiac Pacemaker.
Gahzi AA, Elterman DS, Hassouna M · Int Neurourol J · 2016
- Sacral nerve neuromodulation (InterStim). Part II: Review of programming.
Rittenmeyer H · Urol Nurs · 2008Review
- The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial.
Amundsen CL, Richter HE, Menefee S, et al. · Contemp Clin Trials · 2014Comparative Study, Randomized Controlled Trial
- Sacral Neuromodulation with the InterStimࡊ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study.
Chartier-Kastler E, Le Normand L, Ruffion A, et al. · Eur Urol Focus · 2021Multicenter Study, Observational Study
- Latest technologic and surgical developments in using InterStim Therapy for sacral neuromodulation: impact on treatment success and safety.
Spinelli M, Sievert KD · Eur Urol · 2008Research Support, Non-U.S. Gov't, Review
- [Update on the second line management of idiopathic overactive bladder].
Chartier-Kastler E, Castro-Diaz D, De Ridder D, et al. · Prog Urol · 2009English Abstract, Review
- Prospective, multicenter study to evaluate performance and safety of a re-engineered temporary lead for InterStimࡊ therapy evaluation.
Elterman D, Michaels J, Margolis E, et al. · Neurourol Urodyn · 2022Multicenter Study, Research Support, Non-U.S. Gov't
- [Sacral neuromodulation with InterStimࡊ system: Results from the French national register].
Chartier-Kastler E, Ballanger P, Belas M, et al. · Prog Urol · 2011Clinical Trial, English Abstract
- Sacral Neuromodulation in a Patient with Wolff-Parkinson-White Syndrome: A Case Report.
Almutairi S · Res Rep Urol · 2020Case Reports
Other devices of this type
Also filed under product code QON.
- Axonics Sacral Neuromodulation SystemBoston Scientific Corporation · PMA 2026
- InterStim® Sacral Nerve Stimulation Therapy System / Bowel ControlMedtronic Neuromodulation · PMA 2018
- Verify Evaluation System for Interstim Therapy for Urinary Control and Bowel ControlMedtronic Neuromodulation · PMA 2015
- Test Stimulation Lead Bulk Accessory,test Stimulation Lead KitMedtronic Neuromodulation · PMA 2013
- Model 3058 Interstim II NeurostimulatorMedtronic Neuromodulation · PMA 2012
- Interstim SystemMedtronic Neuromodulation · PMA 2011
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.